Evidence map›Paper›PMID 34683347›Full record

ReviewMicroorganisms2021

Regulation of Resistance in Vancomycin-Resistant Enterococci: The VanRS Two-Component System.

Alexandra A Guffey, Patrick J Loll

Open access · goldAbstract readReview
In one paragraph

Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 63 citations in OpenAlex.

  1. Microorganisms · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Genomic Epidemiology of Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Genome-wide analysis ofJournal of bacteriology · 2025
    Article
  12. Article
  13. Anti-Biofilm Effects of Z102-E ofFoods (Basel, Switzerland) · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alexandra A GuffeyDepartment of Biochemistry & Molecular Biology, College of Medicine, Drexel University, Philadelphia, PA 19102, USA.
Patrick J LollDepartment of Biochemistry & Molecular Biology, College of Medicine, Drexel University, Philadelphia, PA 19102, USA.ORCID 0000-0001-5416-4500
Drexel University · US

Funding

Antibiotic Recognition and Signaling in Vancomycin-Resistant Enterococci (VRE)R01AI148679 · NIAID · DREXEL UNIVERSITY · PI Patrick J Loll · 2020 to 2026
$2.4M
NIAID NIH HHS R01 AI148679NIH HHS 1R01AI148679
6 · The paper itself

Abstract

Vancomycin-resistant enterococci (VRE) are a serious threat to human health, with few treatment options being available. New therapeutics are urgently needed to relieve the health and economic burdens presented by VRE. A potential target for new therapeutics is the VanRS two-component system, which regulates the expression of vancomycin resistance in VRE. VanS is a sensor histidine kinase that detects vancomycin and in turn activates VanR; VanR is a response regulator that, when activated, directs expression of vancomycin-resistance genes. This review of VanRS examines how the expression of vancomycin resistance is regulated, and provides an update on one of the field's most pressing questions: How does VanS sense vancomycin?

Indexed as

antibiotic resistancetwo-component systemvancomycin

Identifiers

PMID34683347
PMCPMC8541618
OpenAlexW3203266714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.